Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283877 | 0.89 | PKN1 (0.64) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL11246587 | 0.87 | CYP1A2 (0.55) | ALDH1A1RAB9AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6169066 | 0.86 | HCRTR1 (0.56) | HCRTR1MMP2MMP13ALDH1A1RAB9A | |
| SCHEMBL1202574 | 0.84 | KDM4E (0.50) | MMP2MMP13ALDH1A1RAB9AKDM4E | |
| SCHEMBL7795891 | 0.83 | HCRTR1 (0.53) | HCRTR1MMP2MMP13ALDH1A1RAB9A | |
| SCHEMBL11824061 | 0.83 | SIRT2 (0.56) | HCRTR1MMP2MMP13ALDH1A1RAB9A | |
| Bromide SCHEMBL214290 | 0.83 | KDM4E (0.49) | MMP2MMP13ALDH1A1RAB9AKDM4E | |
| SCHEMBL20001715 | 0.82 | SIRT2 (0.65) | ALDH1A1RAB9AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL12393020 | 0.82 | ALDH1A1 (0.54) | HCRTR1MMP2MMP13ALDH1A1RAB9A | |
| SCHEMBL12393006 | 0.82 | HRH3 (0.56) | HCRTR1MMP2MMP13ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | 4SC AG (DE) | 2018-06-26 | — | — | US | disclosed |
| US-20160137637-A1 | 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS | 4SC DISCOVERY GMBH (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-3010920-A1 | 2,3-DIHYDROBENZOFURAN-5-YL COMPOUNDS AS DYRK KINASE INHIBITORS | 4SC Discovery GmbH (DE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202638-A9 | 2,3-DIHYDROBENZOFURAN-5-YL COMPOUNDS AS DYRK KINASE INHIBITORS | 4SC DISCOVERY GMBH (DE) | 2016-03-03 | — | — | WO | disclosed |
| WO-2014202638-A1 | 2,3-DIHYDROBENZOFURAN-5-YL COMPOUNDS AS DYRK KINASE INHIBITORS | 4SC DISCOVERY GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
| US-4401817-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
| US-4338329-A | COMBATTING RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4289782-A | PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4230868-A | α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | DYRK2, DYRK1B, DYRK1A | HCRTR1 4299/4885MMP2 1943/4885MMP13 1707/4885 |
| US-20160137637-A1 | 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS | DYRK2, DYRK1B, DYRK1A | HCRTR1 4299/4885MMP2 1943/4885MMP13 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.